Skip to Content

New Drug Approvals Archive - November 2014

November 2014

Lemtrada (alemtuzumab) Injection

Date of Approval: November 14, 2014
Company: Genzyme
Treatment for: Multiple Sclerosis

Lemtrada (alemtuzumab) is a CD52-directed cytolytic monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Read more: Lemtrada (alemtuzumab) FDA Approval History

Hysingla ER (hydrocodone bitartrate) Extended-Release Tablets

Date of Approval: November 20, 2014
Company: Purdue Pharma L.P.
Treatment for: Chronic Pain

Hysingla ER (hydrocodone) is a single-entity (without acetaminophen) extended-release opioid analgesic for around-the-clock management of moderate to severe chronic pain.

Read more: Hysingla ER (hydrocodone bitartrate) FDA Approval History

Onexton (benzoyl peroxide and clindamycin phosphate) Gel

Date of Approval: November 25, 2014
Company: Valeant Pharmaceuticals International, Inc.
Treatment for: Acne

Onexton (benzoyl peroxide and clindamycin phosphate) is an antimicrobial and lincosamide antibacterial combination for the once-daily topical treatment of acne vulgaris.

Read more: Onexton (benzoyl peroxide and clindamycin phosphate) FDA Approval History

New Drug Approvals Archive